{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:04:51Z","timestamp":1782270291863,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Foundation of Gansu Province","award":["grant number 24JRRA297"],"award-info":[{"award-number":["grant number 24JRRA297"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03229-8","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:23:10Z","timestamp":1768285390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2\/ARE-mediated oxidative stress"],"prefix":"10.1007","volume":"43","author":[{"given":"Long","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-2138","authenticated-orcid":false,"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"12","key":"3229_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"18","key":"3229_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Levis MJ. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"3229_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA. Ogba N. Acute myeloid Leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(7):926\u201357.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"3229_CR4","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","volume":"127","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127(8):1186\u2013207.","journal-title":"Cancer"},{"issue":"11","key":"3229_CR5","doi-asserted-by":"publisher","first-page":"e2305885","DOI":"10.1002\/advs.202305885","volume":"11","author":"J Jin","year":"2024","unstructured":"Jin J, Hou S, Yao Y, Liu M, Mao L, Yang M, Wang H. Phosphoproteomic characterization and kinase signature predict response to venetoclax plus 3\u2009+\u20097 chemotherapy in acute myeloid leukemia. Adv Sci (Weinh). 2024;11(11):e2305885.","journal-title":"Adv Sci (Weinh)"},{"key":"3229_CR6","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.2147\/DDDT.S535517","volume":"19","author":"W Shang","year":"2025","unstructured":"Shang W, Li XH, Zeng LH, Li Z, Hu Y, Wen HM. Wan GX. Mechanistic insights into flavonoid subclasses as cardioprotective agents against Doxorubicin-Induced cardiotoxicity: A comprehensive review. Drug Des Devel Ther. 2025;19:5553\u201396.","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"3229_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T. Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32(10):2167\u201377.","journal-title":"Leukemia"},{"issue":"2","key":"3229_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000486228","volume":"139","author":"X Song","year":"2018","unstructured":"Song X, Peng Y, Wang X, Chen Y, Jin L, Yang T, Lan J. Incidence, Survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the Surveillance, Epidemiology, and end results (SEER) Database, 2001\u20132013. Acta Haematol. 2018;139(2):115\u201327.","journal-title":"Acta Haematol"},{"key":"3229_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"25","key":"3229_CR10","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS. Kantarjian HM. Durable remissions with Ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398.","journal-title":"N Engl J Med"},{"key":"3229_CR11","doi-asserted-by":"crossref","unstructured":"Gurnari C, Pagliuca S, Visconte V. Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci, 2020, 21(22):8505.","DOI":"10.3390\/ijms21228505"},{"issue":"4","key":"3229_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.bbrc.2016.03.141","volume":"473","author":"J Yao","year":"2016","unstructured":"Yao J, Wei X, Lu Y. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K\/Akt\/Nrf2 signaling pathway in K562\/Adr human leukemia cells. Biochem Biophys Res Commun. 2016;473(4):867\u201373.","journal-title":"Biochem Biophys Res Commun"},{"key":"3229_CR13","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.mam.2024.101279","volume":"97","author":"K Muzammil","year":"2024","unstructured":"Muzammil K, Sabah Ghnim Z, Saeed Gataa I, Fawzi Al-Hussainy A, Ali Soud N, Adil M. Yasamineh S. NRF2-mediated regulation of lipid pathways in viral infection. Mol Aspects Med. 2024;97:101279.","journal-title":"Mol Aspects Med"},{"key":"3229_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-pharmtox-052220-103416","volume":"62","author":"A Cuadrado","year":"2022","unstructured":"Cuadrado A. Brain-Protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2022;62:255\u201377.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3229_CR15","doi-asserted-by":"publisher","first-page":"103134","DOI":"10.1016\/j.redox.2024.103134","volume":"72","author":"C Morgenstern","year":"2024","unstructured":"Morgenstern C, Lastres-Becker I, Demird\u00f6\u011fen BC, Costa VM, Daiber A, Foresti R. Copple IM. Biomarkers of NRF2 signalling: current status and future challenges. Redox Biol. 2024;72:103134.","journal-title":"Redox Biol"},{"issue":"5","key":"3229_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11262-023-02014-x","volume":"59","author":"MAV Cervantes","year":"2023","unstructured":"Cervantes MAV, Martinez JAV, Garc\u00eda LDG, Ortega OL, Romero HA, Estrada AM. Ju\u00e1rez ML. Zika virus infection induces expression of NRF2 and antioxidant systems in trophoblast cells. Virus Genes. 2023;59(5):781\u20135.","journal-title":"Virus Genes"},{"key":"3229_CR17","doi-asserted-by":"crossref","unstructured":"Blas-Garc\u00eda A, Apostolova N. Novel therapeutic approaches to liver fibrosis based on targeting oxidative stress. Antioxid (Basel), 2023, 12(8):1576.","DOI":"10.3390\/antiox12081567"},{"issue":"2","key":"3229_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12035-023-03559-6","volume":"61","author":"R Lal","year":"2024","unstructured":"Lal R, Dharavath RN, Chopra K. Nrf2 signaling pathway: a potential therapeutic target in combating oxidative stress and neurotoxicity in Chemotherapy-Induced cognitive impairment. Mol Neurobiol. 2024;61(2):593\u2013608.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"3229_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12032-024-02302-y","volume":"41","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V. Maher KR. Venetoclax with decitabine or Azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol. 2024;41(3):80.","journal-title":"Med Oncol"},{"issue":"4","key":"3229_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","volume":"12","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P. Fiedler W. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12(4):71.","journal-title":"Blood Cancer J"},{"key":"3229_CR21","doi-asserted-by":"publisher","first-page":"107370","DOI":"10.1016\/j.leukres.2023.107370","volume":"134","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J. Maher KR. Abbreviated venetoclax with decitabine or Azacitidine in acute myeloid leukemia. Leuk Res. 2023;134:107370.","journal-title":"Leuk Res"},{"issue":"7","key":"3229_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH. Pratz KW. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"3229_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H. L\u00f6wenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"2","key":"3229_CR24","first-page":"187","volume":"67","author":"H Wang","year":"2012","unstructured":"Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Yang W. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Pharmazie. 2012;67(2):187\u201392.","journal-title":"Pharmazie"},{"issue":"1","key":"3229_CR25","doi-asserted-by":"publisher","first-page":"18173","DOI":"10.1038\/s41598-025-03370-4","volume":"15","author":"M Dubois","year":"2025","unstructured":"Dubois M, Goisnard A, Bourgne C, Gay E, Depresle M, Roux M. Bamdad M. P-gp quantification for cell resistance studies in leukemia cells using the innovative LightSpot-FL-1 fluorescent conjugate. Sci Rep. 2025;15(1):18173.","journal-title":"Sci Rep"},{"issue":"11","key":"3229_CR26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood.2023021680","volume":"144","author":"F Mazziotta","year":"2024","unstructured":"Mazziotta F, Biavati L, Rimando J, Rutella S, Borcherding N, Parbhoo S. Luznik L. CD8\u2009+\u2009T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024;144(11):1168\u201382.","journal-title":"Blood"},{"issue":"5","key":"3229_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol. 2021;39(5):419\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3229_CR28","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ. Aifantis I. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27\u201342.","journal-title":"Nat Cancer"},{"issue":"10","key":"3229_CR29","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","volume":"12","author":"A Yeaton","year":"2022","unstructured":"Yeaton A, Cayanan G, Loghavi S, Dolgalev I, Leddin EM, Loo CE. Guillamot M. The impact of Inflammation-Induced tumor plasticity during myeloid transformation. Cancer Discov. 2022;12(10):2392\u2013413.","journal-title":"Cancer Discov"},{"key":"3229_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Y, Knatko EV, Higgins M, Dayalan Naidu S, Smith G, Honda T, Dinkova-Kostova AT. Pirin, an Nrf2-Regulated Protein, is overexpressed in human colorectal tumors. Antioxid (Basel), 2022, 11(2):262.","DOI":"10.3390\/antiox11020262"},{"key":"3229_CR31","doi-asserted-by":"publisher","first-page":"111652","DOI":"10.1016\/j.biopha.2021.111652","volume":"142","author":"C Cheng","year":"2021","unstructured":"Cheng C, Yuan F, Chen XP, Zhang W, Zhao XL, Jiang ZP, Cao S. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother. 2021;142:111652.","journal-title":"Biomed Pharmacother"},{"key":"3229_CR32","doi-asserted-by":"crossref","unstructured":"Panieri E, Buha A, Telkoparan-Akillilar P, Cevik D, Kouretas D, Veskoukis A. Saso L. Potential applications of NRF2 modulators in cancer therapy. Antioxid (Basel), 2020, 9(3):193.","DOI":"10.3390\/antiox9030193"},{"issue":"5","key":"3229_CR33","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cam4.2101","volume":"8","author":"S Wu","year":"2019","unstructured":"Wu S, Lu H, Bai Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 2019;8(5):2252\u201367.","journal-title":"Cancer Med"},{"issue":"16\u201318","key":"3229_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/ars.2023.0409","volume":"41","author":"G Luo","year":"2024","unstructured":"Luo G, Kumar H, Aldridge K, Rieger S, Han E, Jiang E. Letterio JJ. A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multicancer prognosis. Antioxid Redox Signal. 2024;41(16\u201318):1031\u201350.","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"3229_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/2159-8290.CD-21-0922","volume":"12","author":"R Pillai","year":"2022","unstructured":"Pillai R, Hayashi M, Zavitsanou AM, Papagiannakopoulos T. NRF2: keaping tumors protected. Cancer Discov. 2022;12(3):625\u201343.","journal-title":"Cancer Discov"},{"key":"3229_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.freeradbiomed.2021.03.024","volume":"168","author":"S Bader","year":"2021","unstructured":"Bader S, Wilmers J, Pelzer M, Jendrossek V, Rudner J. Activation of anti-oxidant Keap1\/Nrf2 pathway modulates efficacy of dihydroartemisinin-based monotherapy and combinatory therapy with ionizing radiation. Free Radic Biol Med. 2021;168:44\u201354.","journal-title":"Free Radic Biol Med"},{"key":"3229_CR37","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Collette Y, Vey N. Venetoclax resistance in acute myeloid leukemia. Cancers (Basel), 2024, 16(6):1091.","DOI":"10.3390\/cancers16061091"},{"issue":"1","key":"3229_CR38","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/s12885-020-07469-x","volume":"20","author":"R Nishi","year":"2020","unstructured":"Nishi R, Shigemi H, Negoro E, Okura M, Hosono N, Yamauchi T. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and Clofarabine. BMC Cancer. 2020;20(1):984.","journal-title":"BMC Cancer"},{"issue":"24","key":"3229_CR39","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K. Panayiotidis P. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"issue":"6","key":"3229_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/cas.12131","volume":"104","author":"H Shigemi","year":"2013","unstructured":"Shigemi H, Yamauchi T, Tanaka Y, Ueda T. Novel leukemic cell lines resistant to Clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis. Cancer Sci. 2013;104(6):732\u20139.","journal-title":"Cancer Sci"},{"issue":"1","key":"3229_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.20137","volume":"207","author":"Y Luo","year":"2025","unstructured":"Luo Y, Fu Y, Kuang M, Wang J, Zhao R, Luo S, Zhou C. Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis. Br J Haematol. 2025;207(1):46\u201358.","journal-title":"Br J Haematol"},{"key":"3229_CR42","doi-asserted-by":"crossref","unstructured":"Yang C, Gu Y, Ge Z, Song C. Targeting EZH2 promotes chemosensitivity of BCL-2 inhibitor through suppressing PI3K and c-KIT signaling in acute myeloid leukemia. Int J Mol Sci, 2022, 23(19):11393.","DOI":"10.3390\/ijms231911393"},{"key":"3229_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Kumar. AP. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer, 2023, 22(1): 138.","journal-title":"Mol Cancer"},{"issue":"6","key":"3229_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.leu.2404245","volume":"20","author":"AM Martelli","year":"2006","unstructured":"Martelli AM, Ny\u00e5kern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L. Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006;20(6):911\u201328.","journal-title":"Leukemia"},{"issue":"4","key":"3229_CR45","first-page":"984","volume":"4","author":"M Estruch","year":"2021","unstructured":"Estruch M, Vittori C, Montesinos TM, Reckzeh K, Theilgaard-M\u00f6nch K. Targeting of PI3K\/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance. Cancer Drug Resist. 2021;4(4):984\u201395.","journal-title":"Cancer Drug Resist"},{"key":"3229_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fphar.2020.00631","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Peng X, Lang J, Xu C. Targeting mouse double minute 2: current concepts in DNA damage repair and therapeutic approaches in cancer. Front Pharmacol. 2020;11:631.","journal-title":"Front Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03229-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:46:22Z","timestamp":1770389182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03229-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3229"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03229-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}